期刊
JOURNAL OF RHEUMATOLOGY
卷 41, 期 11, 页码 2161-2166出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.140137
关键词
RHEUMATOID ARTHRITIS; REMISSION; DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; OUTCOMES
类别
资金
- Amgen Canada Inc.
- Pfizer Canada Inc.
- Hoffmann-La Roche Ltd.
- United Chemicals of Belgium Canada Inc.
- Bristol-Myers Squibb Canada Co.
- Abbott Laboratories Ltd.
- Janssen Biotech Inc. (a wholly owned subsidiary of Johnson Johnson Inc.)
Objective. To evaluate the prevalence and predictive factors of sustained remission in an early rheumatoid arthritis (ERA) population. Predictive factors of sustained remission in ERA are unknown. We hypothesized that a short time to remission is an important predictor of sustained clinical remission. Methods. Patients in the Canadian Early Arthritis Cohort were included. Remission was defined by Boolean-based American College of Rheumatology/European League Against Rheumatism clinical trial and clinical practice definitions and Simplified Disease Activity Index (SDAI). Logistic regression analysis identified predictors of sustained remission and influence of time to remission. Results. Of 1840 patients, 633 (34%) achieved clinical trial remission, 759 (41%) clinical practice remission, and 727 (39%) SDAI remission. Over half of those meeting remission criteria achieved sustained remission based on clinical trial (55%), clinical practice (60%), and/or SDAI (58%). Corticosteroid use and lack of initial disease-modifying antirheumatic drug (DMARD) were associated with decreased probability of sustained remission, while initial combination DMARD increased this probability. Female sex, greater pain, and longer time to first remission made sustained remission less likely. Conclusion. Female sex, greater pain, and lack of initial DMARD therapy reduced the probability of sustained remission. A shorter time to remission is related to sustainability and supports striving for early remission.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据